Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrronium bromide to reduce salivary iodine uptake during radioiodine imaging
NL-OMON46303Phase 2Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glycopyrronium in thyroid cancer, sponsored by Netherlands Cancer Institute. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
glycopyrronium
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NL-OMON46303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46303.